Defibrotide
- Generic Name
- Defibrotide
- Brand Names
- Defitelio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83712-60-1
- Unique Ingredient Identifier
- 568FY5I1YI
- Background
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a...
- Indication
Indicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
- Associated Conditions
- Sinusoidal Obstruction Syndrome (SOS)
- Associated Therapies
- -
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT06182410
Defibrotide Dose-escalation for SOS Post-HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 20
- Registration Number
- NCT05987124
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Defibrotide in Children With High Risk Kawasaki Disease
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 2
- Registration Number
- NCT04777422
- Locations
- 🇺🇸
Mitchell Cairo, Valhalla, New York, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸New York University, New York, New York, United States
Defibrotide for the Treatment of Severe COVID-19
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04652115
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Gregory Yanik
- Target Recruit Count
- 13
- Registration Number
- NCT04530604
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2023-06-07
- Target Recruit Count
- 156
- Registration Number
- NCT04348383
- Locations
- 🇪🇸
Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
🇪🇸Hospital Clinico y Provincial de Barcelona, Barcelona, Spain
🇪🇸Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain
5-day Defibrotide Treatment for Hepatic SOS/VOD
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 24
- Registration Number
- NCT04313036
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03954106
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 20
- Registration Number
- NCT03805581
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Defibrotide TMA Prophylaxis Pilot Trial
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 25
- Registration Number
- NCT03384693
- Locations
- 🇺🇸
Benioff Children's Hospital at UCSF Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.